RA Capital Management
Investor profile
RA Capital Management has backed 10 European tech companies across 10 funding rounds between 2018 and 2025, joining rounds totalling €1.6B. Most active in Healthtech. Data as of Nov 2026.
Deals
10
distinct rounds
Companies
10
backed
Active span
2018–2025
8 yrs
Total round €
€1.6B
sum of rounds joined
Deals by year
distinct rounds / yearRA Capital Management — deals by year — interactive chart.
Data table
| RA Capital Management — deals by year | |
|---|---|
| 2018 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
Top sectors
by dealsRA Capital Management — top sectors — interactive chart.
Data table
| RA Capital Management — top sectors | |
|---|---|
| Healthtech | 10 |
Stages
by dealsRA Capital Management — stages — interactive chart.
Data table
| RA Capital Management — stages | |
|---|---|
| Other | 3 |
| Series A | 3 |
| Series B | 3 |
| Series D+ | 1 |
Countries
by dealsRA Capital Management — countries — interactive chart.
Data table
| RA Capital Management — countries | |
|---|---|
| UK | 5 |
| Denmark | 1 |
| Germany | 1 |
| Ireland | 1 |
| Israel | 1 |
| Netherlands | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Andera Partners2
- Deep Track Capital2
- Forbion2
- Invus2
- AbbVie Ventures1
- Access Biotechnology1
- Adage Capital Management1
- Avidity Partners1
- Avoro Capital Advisors1
- CaaS Capital Management1
- Casdin Capital1
- CureDuchenne Ventures1
- Deerfield1
- Droia Ventures1
- EcoR1 Capital1
- EQT Life Sciences1
- Fairmount1
- Fidelity Management & Research Company LLC1
- General Atlantic1
- Gray’s Creek Capital Partners1
- HealthCap1
- INKEF Capital1
- IP Group PLC1
- Janus Henderson Investors1
- Laurion Capital Management1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Bicycle Therapeutics | UK | 1 | €512M |
| Verdiva Bio | UK | 1 | €399M |
| Artios | UK | 1 | €198M |
| Hemab Therapeutics | Denmark | 1 | €127M |
| Pepgen | UK | 1 | €95M |
| T-knife | Germany | 1 | €93M |
| Ambagon Therapeutics | Netherlands | 1 | €75M |
| Alchemab Therapeutics | UK | 1 | €69M |
| Nucleix | Israel | 1 | €47M |
| Whiteswell | Ireland | 1 | €26M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Bicycle Therapeutics | Other | €512M | 2024-05 |
| Verdiva Bio | Series A | €399M | 2025-01 |
| Hemab Therapeutics | Series B | €127M | 2023-02 |
| Artios | Series D+ | €99M | 2025-11 |
| Artios | Series D+ | €99M | 2025-11 |
| Pepgen | Other | €95M | 2021-08 |
| T-knife | Series B | €93M | 2021-08 |
| Ambagon Therapeutics | Series A | €75M | 2022-01 |
| Alchemab Therapeutics | Series A | €69M | 2021-04 |
| Nucleix | Other | €47M | 2021-04 |